Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Reuters NewMedia - Thursday, November 18, 1999
Myriad said that the new target may enable the creation of an entirely new class of therapeutics, distinct from the protease inhibitors or reverse-transcriptase inhibitors which are the most commonly prescribed among the current generation of HIV drugs.
The target has not been licensed to another company and represents Myriad's seventh internal drug development program.
Assays for drugs that modify the target have been created in preparation for high-throughput screening by Myriad Pharmaceuticals Inc., the company's wholly owned subsidiary.
"This new HIV drug target is especially exciting in that it has the potential to improve on current treatments for AIDS," said Adrian Hobden, president of Myriad Pharmaceuticals, in a statement.
"With the evolution of multi-drug resistant strains of the virus comes an increased need for therapies that act through different mechanisms," Hobden said.
991118
RE991105
Copyright © 1999 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .